NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
66658-0112-01 | 66658-0112 | Palifermin | Kepivance | 6.25 mg/1.2mL | Ancillary Therapy | Epithelial Growth Factor | Keratinocyte Growth Factor/rHuKGF | Intravenous | Nov 14, 2012 | Apr 30, 2023 | No Longer Used |
66658-0112-24 | 66658-0112 | Palifermin | Kepivance | 6.25 mg/1.2mL | Ancillary Therapy | Epithelial Growth Factor | Keratinocyte Growth Factor/rHuKGF | Intravenous | Dec 15, 2009 | Apr 1, 2016 | No Longer Used |
55513-0520-01 | 55513-0520 | Palifermin | Kepivance | Ancillary Therapy | Epithelial Growth Factor | Keratinocyte Growth Factor/rHuKGF | Dec 15, 2004 | Dec 15, 2009 | No Longer Used | ||
66658-0113-03 | 66658-0113 | Palifermin | KEPIVANCE | 5.16 mg/1.2mL | Ancillary Therapy | Epithelial Growth Factor | Keratinocyte Growth Factor/rHuKGF | Intravenous | Aug 4, 2023 | In Use | |
00245-0825-30 | 00245-0825 | Everolimus | TORPENZ | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 24, 2024 | In Use | |
63850-0060-04 | 63850-0060 | Everolimus | Everolimus | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | May 26, 2023 | In Use | |
82950-0001-16 | 82950-0001 | TOVORAFENIB | OJEMDA | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF, CRAF | Oral | Apr 30, 2024 | In Use | |
00069-0353-30 | 00069-0353 | Talazoparib | Talzenna | 0.25 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Apr 17, 2024 | In Use | |
63850-0128-02 | 63850-0128 | Everolimus | Everolimus | 2.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jan 30, 2025 | In Use | |
00074-0576-34 | 00074-0576 | Venetoclax | Venclexta | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BCL-2 | Oral | Nov 21, 2018 | In Use | |
51991-0821-33 | 51991-0821 | Everolimus | Everolimus | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 5, 2023 | In Use | |
00078-0628-51 | 00078-0628 | Everolimus | Afinitor | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Aug 29, 2012 | In Use | |
00069-0454-30 | 00069-0454 | Talazoparib | Talzenna | 0.35 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Apr 17, 2024 | In Use | |
60219-2280-02 | 60219-2280 | Everolimus | EVEROLIMUS | 3.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jan 14, 2025 | In Use | |
00310-0657-58 | 00310-0657 | Olaparib | Lynparza | 50.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Dec 24, 2014 | Mar 31, 2020 | No Longer Used |
72237-0101-01 | 72237-0101 | Selinexor | XPOVIO | 20.0 mg/1 | Chemotherapy | Enzyme Inhibitor | XPO1 | Oral | Jul 10, 2019 | In Use | |
70377-0012-23 | 70377-0012 | Everolimus | EVEROLIMUS | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | May 17, 2024 | In Use | |
00310-0679-95 | 00310-0679 | Olaparib | Lynparza | 150.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Aug 31, 2017 | In Use | |
00093-7768-24 | 00093-7768 | Everolimus | Everolimus | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 10, 2020 | In Use | |
00054-0497-14 | 00054-0497 | Everolimus | Everolimus | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 8, 2020 | In Use | |
00069-0252-30 | 00069-0252 | Talazoparib | Talzenna | 0.1 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Apr 17, 2024 | In Use | |
70377-0013-22 | 70377-0013 | Everolimus | EVEROLIMUS | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Oct 1, 2021 | In Use | |
00078-0594-61 | 00078-0594 | Everolimus | Afinitor | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jul 9, 2010 | In Use | |
63850-0058-01 | 63850-0058 | Everolimus | Everolimus | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Mar 5, 2021 | In Use | |
72694-0617-60 | 72694-0617 | Ivosidenib | Tibsovo | 250.0 mg/1 | Chemotherapy | Enzyme Inhibitor | IDH1 | Oral | Oct 19, 2021 | In Use |
Found 11465 results — Export these results